Beam Therapeutics Stock Performance
| BEAM Stock | USD 23.30 0.43 1.88% |
The firm shows a Beta (market volatility) of 1.25, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Beam Therapeutics will likely underperform. At this point, Beam Therapeutics has a negative expected return of -0.25%. Please make sure to confirm Beam Therapeutics' coefficient of variation, value at risk, rate of daily change, as well as the relationship between the total risk alpha and kurtosis , to decide if Beam Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Beam Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 1.88 | Five Day Return (2.55) | Year To Date Return (5.67) | Ten Year Return 24.27 | All Time Return 24.27 |
1 | Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3 | 12/24/2024 |
2 | Beam Therapeutics Inc.s Prospects Need A Boost To Lift Shares | 01/31/2025 |
3 | Wall Street Analysts See a 67.27 percent Upside in Beam Therapeutics Can the Stock Really Move This High | 02/13/2025 |
4 | Disposition of 6287 shares by Bethany Cavanagh of Beam Therapeutics at 35.0 subject to Rule 16b-3 | 02/20/2025 |
5 | Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences | 02/24/2025 |
6 | Beam Therapeutics Inc Q4 2024 Earnings EPS of -1.09 Beats Estimate, Revenue Surges to 30. ... | 02/26/2025 |
7 | TCR Therapy Clinical Trial Pipeline Accelerates as 80 Pharma Companies Rigorously Developing Drugs for the Market Entry DelveInsight | 03/06/2025 |
8 | Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises 500 Million Via Equity | 03/10/2025 |
9 | BEAM Down Despite Positive Initial Data From Genetic Disorder Study | 03/11/2025 |
10 | Beam Therapeutics price target raised by 8 at Citi, heres why BEAM | 03/13/2025 |
11 | Acquisition by Walsh Kathleen E of 23114 shares of Beam Therapeutics at 24.49 subject to Rule 16b-3 | 03/17/2025 |
12 | CRISPR Therapeutics Stock Trades Near 52-Week Low Time to Buy or Sell | 03/19/2025 |
13 | Yiheng Capital Management L.P. Sells 337,658 Shares of Beam Therapeutics Inc. | 03/21/2025 |
| Begin Period Cash Flow | 444.6 M |
Beam |
Beam Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,870 in Beam Therapeutics on December 22, 2024 and sell it today you would lose (540.00) from holding Beam Therapeutics or give up 18.82% of portfolio value over 90 days. Beam Therapeutics is currently does not generate positive expected returns and assumes 4.4984% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Beam, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Beam Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Beam Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Beam Therapeutics, and traders can use it to determine the average amount a Beam Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.055
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BEAM |
Estimated Market Risk
| 4.5 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Beam Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Beam Therapeutics by adding Beam Therapeutics to a well-diversified portfolio.
Beam Therapeutics Fundamentals Growth
Beam Stock prices reflect investors' perceptions of the future prospects and financial health of Beam Therapeutics, and Beam Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Beam Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (3.33) % | ||||
| Current Valuation | 1.64 B | ||||
| Shares Outstanding | 99.84 M | ||||
| Price To Earning | 37.48 X | ||||
| Price To Book | 3.17 X | ||||
| Price To Sales | 36.62 X | ||||
| Revenue | 63.52 M | ||||
| Gross Profit | (304.04 M) | ||||
| EBITDA | (415.57 M) | ||||
| Net Income | (376.74 M) | ||||
| Cash And Equivalents | 1.09 B | ||||
| Cash Per Share | 15.90 X | ||||
| Total Debt | 161.43 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 4.64 X | ||||
| Book Value Per Share | 9.05 X | ||||
| Cash Flow From Operations | (347.25 M) | ||||
| Earnings Per Share | (4.67) X | ||||
| Market Capitalization | 2.33 B | ||||
| Total Asset | 1.1 B | ||||
| Retained Earnings | (1.57 B) | ||||
| Working Capital | 696.08 M | ||||
| Current Asset | 2.89 B | ||||
| Current Liabilities | 706.6 M | ||||
About Beam Therapeutics Performance
By examining Beam Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Beam Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Beam Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -12.1 K | -12.7 K | |
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.45) | (0.43) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.51) | (0.54) |
Things to note about Beam Therapeutics performance evaluation
Checking the ongoing alerts about Beam Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Beam Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Beam Therapeutics generated a negative expected return over the last 90 days | |
| Beam Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 63.52 M. Net Loss for the year was (376.74 M) with loss before overhead, payroll, taxes, and interest of (304.04 M). | |
| Beam Therapeutics currently holds about 1.09 B in cash with (347.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Beam Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 79.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Yiheng Capital Management L.P. Sells 337,658 Shares of Beam Therapeutics Inc. |
- Analyzing Beam Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Beam Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Beam Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Beam Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Beam Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Beam Therapeutics' stock. These opinions can provide insight into Beam Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.67) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.